Anticoagulation After GI Bleeding Pilot Study and Registry
Post-Bleed Management of Antithrombotic Therapy After Gastrointestinal Bleeding: Pilot Study and Registry (PANTHER-GI)
Ottawa Hospital Research Institute
100 participants
Mar 31, 2022
INTERVENTIONAL
Conditions
Summary
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related gastrointestinal (GI) bleeding among patients at moderate to high risk of re-bleeding and thrombosis. A parallel registry will assess whether eligible patients who are not enrolled in the PANTHER-GI Pilot Study are systematically different than enrolled patients and to explore barriers to enrolment.
Eligibility
Inclusion Criteria8
- Male or female subjects aged 18 years or older
- Hospitalized with acute major non-variceal GI bleeding (defined as per ISTH criteria) while receiving OAC therapy (warfarin or DOAC).
- OAC therapy discontinued for current acute GI bleed and not yet resumed
- Ongoing indication for long-term anticoagulation of atrial fibrillation (moderate to high risk of stroke/systemic embolism with CHA2DS2VASc score of 3 or higher) or VTE (as per clinical care team)
- Planned to resume DOAC post-bleed
- At moderate to high risk of re-bleeding as per clinical care team
- Clinical hemostasis achieved as per clinical care team
- Able and willing to comply with follow-up examinations contained within the consent form
Exclusion Criteria7
- Mechanical heart valve
- VTE in the context of major transient risk factor and completed 3 months of treatment
- GI bleeding managed surgically (e.g. gastrectomy, colectomy)
- Active or previously treated gastrointestinal cancer
- Life expectancy from other causes of less than 3 months
- Platelet count < 50,000/µL (or < 50x109/L)
- Renal dysfunction (Creatine Clearance <30 mL/min as calculated by the Cockcroft-Gault formula)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team). High thrombotic risk includes the following: (i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator
In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team). Moderate thrombotic risk includes the following: (i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05290857